Myasthenia Gravis - Pipeline Insight, 2022
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Myasthenia Gravis – Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Myasthenia Gravis: Overview
Myasthenia gravis (MG) is the most common disorder affecting the neuromuscular junction (NMJ) of the skeletal muscles. The classic presentation is a fluctuating weakness that is more prominent in the afternoon. It usually involves muscles of the eyes, throat, and extremities. The reduced transmission of electrical impulses across the neuromuscular junction due to the formation of autoantibodies against the specific postsynaptic membrane proteins consequently causes muscle weakness. A wide variety of conditions can precipitate MG, such as infections, immunization, surgeries, and drugs. Myasthenia gravis causes a significant number of complications. These include myasthenic crisis, an acute respiratory paralysis that requires intensive care, as well as adverse events due to long term medication treatment like opportunistic infections and lymphoproliferative malignancies. A complete understanding of the pathophysiologic mechanisms, clinical manifestations, treatment strategies, and complications of myasthenia gravis is necessary for better patient care and outcomes.
'Myasthenia Gravis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myasthenia Gravis pipeline landscape is provided which includes the disease overview and Myasthenia Gravis treatment guidelines. The assessment part of the report embraces, in depth Myasthenia Gravis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myasthenia Gravis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Myasthenia Gravis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myasthenia Gravis Emerging Drugs
Further product details are provided in the report……..
Myasthenia Gravis: Therapeutic Assessment
This segment of the report provides insights about the different Myasthenia Gravis drugs segregated based on following parameters that define the scope of the report, such as:
Myasthenia Gravis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myasthenia Gravis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myasthenia Gravis drugs.
Myasthenia Gravis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Myasthenia Gravis – Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Myasthenia Gravis: Overview
Myasthenia gravis (MG) is the most common disorder affecting the neuromuscular junction (NMJ) of the skeletal muscles. The classic presentation is a fluctuating weakness that is more prominent in the afternoon. It usually involves muscles of the eyes, throat, and extremities. The reduced transmission of electrical impulses across the neuromuscular junction due to the formation of autoantibodies against the specific postsynaptic membrane proteins consequently causes muscle weakness. A wide variety of conditions can precipitate MG, such as infections, immunization, surgeries, and drugs. Myasthenia gravis causes a significant number of complications. These include myasthenic crisis, an acute respiratory paralysis that requires intensive care, as well as adverse events due to long term medication treatment like opportunistic infections and lymphoproliferative malignancies. A complete understanding of the pathophysiologic mechanisms, clinical manifestations, treatment strategies, and complications of myasthenia gravis is necessary for better patient care and outcomes.
'Myasthenia Gravis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myasthenia Gravis pipeline landscape is provided which includes the disease overview and Myasthenia Gravis treatment guidelines. The assessment part of the report embraces, in depth Myasthenia Gravis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myasthenia Gravis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Myasthenia Gravis R&D. The therapies under development are focused on novel approaches to treat/improve Myasthenia Gravis.
This segment of the Myasthenia Gravis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myasthenia Gravis Emerging Drugs
- Efgartigimod: Argenx
- Ravulizumab: Alexion Pharmaceuticals
- Inebilizumab: Horizon Therapeutics
Further product details are provided in the report……..
Myasthenia Gravis: Therapeutic Assessment
This segment of the report provides insights about the different Myasthenia Gravis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Myasthenia Gravis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Myasthenia Gravis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myasthenia Gravis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myasthenia Gravis drugs.
Myasthenia Gravis Report Insights
- Myasthenia Gravis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Myasthenia Gravis drugs?
- How many Myasthenia Gravis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myasthenia Gravis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myasthenia Gravis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myasthenia Gravis and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Myasthenia Gravis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Efgartigimod: Argenx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DAS-001: DAS Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
Descartes-08: Cartesian Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Myasthenia Gravis Key Companies
Myasthenia Gravis Key Products
Myasthenia Gravis- Unmet Needs
Myasthenia Gravis- Market Drivers and Barriers
Myasthenia Gravis- Future Perspectives and Conclusion
Myasthenia Gravis Analyst Views
Myasthenia Gravis Key Companies
Appendix
Executive Summary
Myasthenia Gravis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Efgartigimod: Argenx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DAS-001: DAS Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
Descartes-08: Cartesian Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Myasthenia Gravis Key Companies
Myasthenia Gravis Key Products
Myasthenia Gravis- Unmet Needs
Myasthenia Gravis- Market Drivers and Barriers
Myasthenia Gravis- Future Perspectives and Conclusion
Myasthenia Gravis Analyst Views
Myasthenia Gravis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Myasthenia Gravis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Myasthenia Gravis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Myasthenia Gravis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Myasthenia Gravis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
